FDA WARNING_LETTER - Medtronic Inc. Cardiac Rhythm Disease Managment - August 06, 2009

The FDA issued a Warning Letter to Medtronic's Cardiac Rhythm Disease Management business unit following an inspection from June 8 to August 6, 2009, which found their implantable pacemakers and leads to be adulterated under 21 U.S.C. § 351(h). The inspection revealed non-conformity with Quality System (QS) regulation (21 CFR Part 820).

Key violations included: 1. **Failure to establish and maintain adequate corrective and preventive action (CAPA) procedures (21 CFR 820.100(a)(2 and 3))**: Medtronic failed to consistently handle investigations and identify actions for nonconformities. Specifically, Field Product Impact Reports (FPIRs) and field corrective actions for recurring device failures (Sigma and Kappa pacemakers) were not uniformly completed. CAPAs were closed despite predicted clinical event numbers being exceeded, and new CAPAs/recalls were significantly delayed, leading to many more failures than predicted. 2. **Failure to follow procedures for design change validation/verification (21 CFR 820.30(i))**: Measurement equipment for component evaluation did not meet accuracy requirements, leading to reliance solely on supplier measurements. Component qualification plans lacked complete tests, acceptance criteria, and were not fully followed regarding testing percentages. 3. **Failure to implement CAPA documentation procedures (21 CFR 820.1